Skip to content
Incyte
-
Incyte buys Vega Therapeutics for US$2B to boost rare bleeding disorder pipeline
The agreement includes an upfront payment of US$1.25 billion, with additional milestone-based payments of up to US$750 million tied to future sales performance.